|
1
|
Moan JE, Baturaite Z, Dahlback A and
Porojnicu AC: Ultraviolet radiation and cutaneous malignant
melanoma. Adv Exp Med Biol. 810:359–374. 2014.PubMed/NCBI
|
|
2
|
Law MH, Bishop DT, Lee JE, Brossard M,
Martin NG, Moses EK, Song F, Barrett JH, Kumar R, Easton DF, et al:
GenoMEL Consortium; Essen-Heidelberg Investigators; SDH Study
Group; Q-MEGA and QTWIN Investigators; AMFS Investigators; ATHENS
Melanoma Study Group: Genome-wide meta-analysis identifies five new
susceptibility loci for cutaneous malignant melanoma. Nat Genet.
47:987–995. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Emri G, Emri E, Boros G, Hegedűs C, Janka
E, Gellén E and Remenyik E: Skin carcinogenesis: the pathogenetic
and therapeutic role of zinc. J Metallomics Nanotechnol. 2:19–26.
2015.
|
|
4
|
Atkins GB and Jain MK: Role of
Krüppel-like transcription factors in endothelial biology. Circ
Res. 100:1686–1695. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
DiFeo A, Martignetti JA and Narla G: The
role of KLF6 and its splice variants in cancer therapy. Drug Resist
Updat. 12:1–7. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Narla G, DiFeo A, Yao S, Banno A, Hod E,
Reeves HL, Qiao RF, Camacho-Vanegas O, Levine A, Kirschenbaum A, et
al: Targeted inhibition of the KLF6 splice variant, KLF6 SV1,
suppresses prostate cancer cell growth and spread. Cancer Res.
65:5761–5768. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Reeves HL, Narla G, Ogunbiyi O, Haq AI,
Katz A, Benzeno S, Hod E, Harpaz N, Goldberg S and Tal-Kremer S:
Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently
inactivated in colorectal cancer. Gastroenterology. 126:1090–1103.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kremer-Tal S, Reeves HL, Narla G, Thung
SN, Schwartz M, Difeo A, Katz A, Bruix J, Bioulac-Sage P,
Martignetti JA, et al: Frequent inactivation of the tumor
suppressor Kruppel-like factor 6 (KLF6) in hepatocellular
carcinoma. Hepatology. 40:1047–1052. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ebrahimi A, Nodushan SMHT, Mousavian A,
Mokarizadeh A, Abbasi M, Yahaghi E and Rasaei SM: Diagnostic and
prognostic potentials of KLF6 and HER3 expression alterations in
cutaneous malignant melanoma. Tumour Biol. Oct 16–2015.(Epub ahead
of print). View Article : Google Scholar
|
|
10
|
Cai D, Zhao J and Sun Q: Kruppel-like
factor 6 in the progression and prognosis of malignant melanoma. J
Int Med Res. 42:184–190. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lin WM, Baker AC, Beroukhim R, Winckler W,
Feng W, Marmion JM, Laine E, Greulich H, Tseng H, Gates C, et al:
Modeling genomic diversity and tumor dependency in malignant
melanoma. Cancer Res. 68:664–673. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Goff LA, Davila J, Swerdel MR, Moore JC,
Cohen RI, Wu H, Sun YE and Hart RP: Ago2 immunoprecipitation
identifies predicted microRNAs in human embryonic stem cells and
neural precursors. PLoS One. 4:e71922009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rönnau CG, Verhaegh GW, Luna-Velez MV and
Schalken JA: Noncoding RNAs as novel biomarkers in prostate cancer.
Biomed Res Int. 2014:5917032014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pouliot LM, Shen D-W, Suzuki T, Hall MD
and Gottesman MM: Contributions of microRNA dysregulation to
cisplatin resistance in adenocarcinoma cells. Exp Cell Res.
319:566–574. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jing L, Jin C, Lu Y, Huo P, Zhou L, Wang Y
and Tian Y: Investigation of microRNA expression profiles
associated with human alcoholic cardiomyopathy. Cardiology.
130:223–233. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gao S, Wang J, Xie J, Zhang T and Dong P:
Role of miR-138 in the regulation of larynx carcinoma cell
metastases. Tumour Biol. Oct 24–2015.(Epub ahead of print).
|
|
17
|
Song K, Liu N, Yang Y and Qiu X:
Regulation of osteosarcoma cell invasion through osteopontin
modification by miR-4262. Tumour Biol. 37:6493–6499. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bao H, Gao F, Xie G and Liu Z:
Angiotensin-converting enzyme 2 inhibits apoptosis of pulmonary
endothelial cells during acute lung injury through suppressing
miR-4262. Cell Physiol Biochem. 37:759–767. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang X, Le Q-T and Giaccia AJ: MiR-210 -
micromanager of the hypoxia pathway. Trends Mol Med. 16:230–237.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chan YC, Banerjee J, Choi SY and Sen CK:
miR-210: The master hypoxamir. Microcirculation. 19:215–223. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang H, Flach H, Onizawa M, Wei L, McManus
MT and Weiss A: Negative regulation of Hif1a expression and TH17
differentiation by the hypoxia-regulated microRNA miR-210. Nat
Immunol. 15:393–401. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qin Q, Furong W and Baosheng L: Multiple
functions of hypoxia-regulated miR-210 in cancer. J Exp Clin Cancer
Res. 33:502014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hatami R, Sieuwerts AM, Izadmehr S, Yao Z,
Qiao RF, Papa L, Look MP, Smid M, Ohlssen J, Levine AC, et al:
KLF6-SV1 drives breast cancer metastasis and is associated with
poor survival. Sci Transl Med. 5:169ra12. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhenzhen Z, De'an T, Limin X, Wei Y and
Min L: New candidate tumor-suppressor gene KLF6 and its splice
variant KLF6 SV2 counterbalancing expression in primary
hepatocarcinoma. Hepatogastroenterology. 59:473–476. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Andreoli V, Gehrau RC and Bocco JL:
Biology of Krüppel-like factor 6 transcriptional regulator in cell
life and death. IUBMB Life. 62:896–905. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen CH, Huang PH, Chu PC, Chen MC, Chou
CC, Wang D, Kulp SK, Teng CM, Wang Q and Chen CS: Energy
restriction-mimetic agents induce apoptosis in prostate cancer
cells in part through epigenetic activation of KLF6 tumor
suppressor gene expression. J Biol Chem. 286:9968–9976. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lang UE, Kocabayoglu P, Cheng GZ,
Ghiassi-Nejad Z, Muñoz U, Vetter D, Eckstein DA, Hannivoort RA,
Walsh MJ and Friedman SL: GSK3β phosphorylation of the KLF6 tumor
suppressor promotes its transactivation of p21. Oncogene.
32:4557–4564. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sangodkar J, Dhawan NS, Melville H, Singh
VJ, Yuan E, Rana H, Izadmehr S, Farrington C, Mazhar S, Katz S, et
al: Targeting the FOXO1/KLF6 axis regulates EGFR signaling and
treatment response. J Clin Invest. 122:2637–2651. 2012. View Article : Google Scholar : PubMed/NCBI
|
